Cellectar Biosciences Highlights Interim Data From Its Ongoing Study Of Iopofosine I 131 In Multiple Myeloma In An Oral Presentation At The SNMMI Annual Meeting
Portfolio Pulse from Happy Mohamed
Cellectar Biosciences, Inc. (NASDAQ:CLRB) presented interim data from its ongoing study of iopofosine I 131 in multiple myeloma at the SNMMI Annual Meeting. The data showed an overall response rate of 28%, a clinical benefit rate of 70%, and a disease control rate of 92% in 64 evaluable patients. The company's COO, Jarrod Longcor, highlighted the outcomes from two dose levels across these highly refractory patients. The FDA has granted Fast Track and Orphan Drug Designations for iopofosine in patients with r/r MM.
June 28, 2023 | 12:37 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Cellectar Biosciences presented positive interim data from its ongoing study of iopofosine I 131 in multiple myeloma, which could potentially boost investor confidence in the company's research and development capabilities.
The positive interim data from the ongoing study of iopofosine I 131 in multiple myeloma patients indicates that the drug is showing promising results. This could potentially lead to increased investor confidence in the company's research and development capabilities, which could positively impact the company's stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100